ISSN : 0975-9492
CODEN : IJPSQQ





INTERNATIONAL JOURNAL OF PHARMA SCIENCES AND RESEARCH


Open Access

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information:
verify here.

ABSTRACT

Title : The genetic basis of the clinical diversity of the Trans-Resveratrol therapy in beta-thalassemic and sickle cell anaemia patients
Authors : Anirban Roy Chowdhury, Sudipa Chakravarty, Amit Chakravarty
Keywords : Resveratrol, -thalassemia, HbF , Blood transfusion, Good responder, Moderate responder, Nonresponder.
Issue Date : Oct 2017
Abstract :
Trans-Resveratrol responses were influenced by Several genetic, non-genetic and pharmacological factors in different early studies. The response to Trans-Resveratrol is significantly different among good, moderate and non-responders irrespective of the IVS I-5 (G?C), the common beta mutation here and even among other 0 or + thalassaemia mutations. It has been shown that even among good responders in some cases (8.39 %) patients are not showing high HbF values. ( < 20% HbF values are taken). We studied among 220 patients that Trans-Resveratrol therapy completely replace blood transfusion in Eastern part of India. The predominant -thalassemia defect is the IVSI-5(G?C), the most frequent 0- thal mutation in the area. This mutation is found in 87.66% of the CR patients and in 86.66% of the PR / NR patients. The next represented defects are the +-thalassemia mutations like Cod 8/9, Fr. 41/42, Cod 15, Cod 30 etc. The distribution of the IVSI-5 (G?C) genotype among the CR, PR / NR. The common IVSI-5 (G?C) mutation in beta thalassemia patients (either in homozygous or heterozygous form) is present in 31.5% among the good responders (CR) while it is present in 66.66% among PR / NR ( moderate responders / non-responders) and in HbE-beta patients present in 73.28% among good responders (CR) while in 33.33% among moderate / non responders (PR / NR).
Page(s) : 211-214
ISSN : 0975-9492
Source : Vol. 8, No.11